ReviewCurrent rheumatology reports2018
Update on the Gastrointestinal Microbiome in Systemic Sclerosis.
Review in Current rheumatology reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 2 syntheses or guidelines pooled it, 55 citations in OpenAlex.
- The Relationship Between Microbiota, Nutrition, and Gastrointestinal Tract Symptoms in Patients with Systemic Sclerosis: A Systematic Review of the Literature.International journal of molecular sciences · 2025Pooled it
- Efficacy and safety of gut microbiota-based therapies in autoimmune and rheumatic diseases: a systematic review and meta-analysis of 80 randomized controlled trials.BMC medicine · 2024Pooled it
- International Investigation of the Gut-Lung Axis in Systemic Sclerosis-Interstitial Lung Disease.Arthritis care & research · 2026Article
- Advancing Gastrointestinal Microbiota Research in Systemic Sclerosis: Lessons Learned from Prior Research and Opportunities to Accelerate Discovery.Rheumatic diseases clinics of North America · 2025Review
- Elevated Circulating Levels of Gut Microbe-Derived TrimethylamineJournal of clinical medicine · 2024Article
- Serum markers of microbial translocation and intestinal damage in assessment of gastrointestinal tract involvement in systemic sclerosis.Clinical and experimental medicine · 2024Article
- Review
- The potential pathogenic role of gut microbiota in rheumatic diseases: a human-centred narrative review.Internal and emergency medicine · 2024Review
- Gastrointestinal tract involvement in systemic sclerosis: The roles of diet and the microbiome.Seminars in arthritis and rheumatism · 2023Article
- Fecal microbiome in systemic sclerosis, in search for the best candidate for microbiota-targeted therapy for small intestinal bacterial overgrowth control.Journal of scleroderma and related disorders · 2022Article
- The Role of Exposomes in the Pathophysiology of Autoimmune Diseases II: Pathogens.Pathophysiology : the official journal of the International Society for Pathophysiology · 2022Review
- The relationship between elevated plasma zonulin levels and Hashimoto's thyroiditis.Turkish journal of medical sciences · 2022Article
- Symptoms related to gastrointestinal tract involvement and low muscularity in systemic sclerosis.Clinical rheumatology · 2022Article
- The Interplay between Autonomic Nervous System and Inflammation across Systemic Autoimmune Diseases.International journal of molecular sciences · 2022Review
- Predicting the Progression of Very Early Systemic Sclerosis: Current Insights.Open access rheumatology : research and reviews · 2022Review
- Inflammation-type dysbiosis of the oral microbiome associates with the duration of COVID-19 symptoms and long COVID.JCI insight · 2021Article
- OralMicroorganisms · 2021Article
- Butyrate Improves Skin/Lung Fibrosis and Intestinal Dysbiosis in Bleomycin-Induced Mouse Models.International journal of molecular sciences · 2021Article
- Congruent microbiome signatures in fibrosis-prone autoimmune diseases: IgG4-related disease and systemic sclerosis.Genome medicine · 2021Article
- Alterations in the gut bacterial microbiome in people with type 2 diabetes mellitus and diabetic retinopathy.Scientific reports · 2021Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewAccumulating evidence suggests that gut microbiota affect the development and function of the immune system and may play a role in the pathogenesis of autoimmune diseases. The purpose of this review is to summarize recent studies reporting gastrointestinal microbiota aberrations associated with the systemic sclerosis disease state. RECENT
findingsThe studies described herein have identified common changes in gut microbial composition. Specifically, patients with SSc have decreased abundance of beneficial commensal genera (e.g., Faecalibacterium, Clostridium, and Bacteroides) and increased abundance of pathobiont genera (e.g., Fusobacterium, Prevotella, Erwinia). In addition, some studies have linked specific genera with the severity of gastrointestinal symptoms in systemic sclerosis. More research is needed to further characterize the gastrointestinal microbiota in systemic sclerosis and understand how microbiota perturbations can affect inflammation, fibrosis, and clinical outcomes. Interventional studies aimed at addressing/correcting these perturbations, either through dietary modification, pro/pre-biotic supplementation, or fecal transplantation, may lead to improved outcomes for patients with systemic sclerosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.